Prevalence of Rotavirus Genotypes Among Children Under Five in Central Asia: A Systematic Review and Meta-Analysis of Available Evidence
Abstract
Background/Objectives: Rotavirus remains a major cause of acute gastroenteritis among children under five years of age, particularly in regions with heterogeneous vaccine implementation. In Central Asia, differences in the timing and coverage of rotavirus vaccination may influence circulating genotype patterns, yet regional evidence remains fragmented. Methods: A systematic review and meta-analysis were conducted in accordance with PRISMA 2020 guidelines and registered in PROSPERO (CRD420251274198). Electronic databases (PubMed, Web of Science, ScienceDirect, and Google Scholar) were searched without date restrictions. Studies reporting laboratory-confirmed rotavirus infection and genotype distribution among children under five years in Central Asia were included. Random-effects meta-analysis of proportions was performed to estimate the pooled genotype proportions among rotavirus-positive children, with subgroup analyses comparing the before and after vaccine introduction periods. Results: Six studies (ten before vaccine introduction strata and four after vaccine introduction strata; N = 1713 rotavirus-positive children) were included. A significant decline in the G1P[8] genotype was observed following vaccine introduction, with pooled prevalence decreasing from 0.468 (95% CI: 0.363–0.577) to 0.068 (95% CI: 0.034–0.133) (p 90%), and evidence certainty was very low for all genotype outcomes. Conclusions: The available evidence suggests that rotavirus genotype distribution…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 1,713 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.